Deep Track Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Deep Track Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$189M	Buy	3,307,481 +2,157,481	+188%	+$118M	2.75%	11
2026 Q1	$65M	Sell	1,150,000 -1,150,000	-50%	-$67.1M	1.06%	27
2025 Q4	$137M	Buy	2,300,000 +2,275,144	+9,153%	+$124M	2.44%	13
2025 Q3	$1.35M	Buy	+24,856	New	+$1.42M	0.04%	54
2023 Q1	–	Sell	-189,800	Closed	-$19.6M	–	63
2022 Q4	$19.6M	Sell	189,800 -549,063	-74%	-$51.5M	0.82%	39
2022 Q3	$62.6M	Buy	738,863 +84,498	+13%	+$7.52M	2.87%	10
2022 Q2	$54.2M	Buy	+654,365	New	+$52.1M	3.56%	9

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Deep Track Capital's BMRN Position: Q2 2026 in Review

Deep Track Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 188% in Q2 2026, buying an estimated $118M and bringing the position to 3,307,481 shares worth $189M. The position accounts for 2.75% of the portfolio, ranked #11.

Deep Track Capital first reported a position in BMRN in Q2 2022 and has held it in 7 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Deep Track Capital held 3,307,481 shares of BioMarin Pharmaceuticals worth $189M as of Q2 2026.
Deep Track Capital bought 2,157,481 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $118M.
BioMarin Pharmaceuticals made up 2.75% of Deep Track Capital's portfolio in Q2 2026, its #11 holding.
Deep Track Capital first reported a position in BioMarin Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.